Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Model studies in adjuvant chemotherapy.

J H Mulder, J de Ruiter, M B Edelstein

    Cancer Treatment Reports
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Multiscale X-ray scattering elucidates activation and deactivation of oxide-derived copper electrocatalysts for CO<sub>2</sub> reduction.

    Nature communications·2025
    Same author

    Anaesthesia for children with cancer.

    BJA education·2024
    Same author

    The novel Mechanical Ventilator Milano for the COVID-19 pandemic.

    Physics of fluids (Woodbury, N.Y. : 1994)·2021
    Same author

    Pediatric chemotherapy.

    Pediatric annals·2014
    Same author

    Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus.

    Annals of the rheumatic diseases·2009
    Same author

    The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis.

    Infection·2009
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Adjuvant chemotherapy timing significantly impacts efficacy in mouse models, with preoperative treatment beneficial for some tumors but detrimental to others. Cure rates improve with lower residual tumor loads, but lifespan increases are unrelated to tumor size.

    Area of Science:

    • Oncology
    • Cancer Research
    • Pharmacology

    Background:

    • Adjuvant chemotherapy is crucial for treating residual cancer post-surgery.
    • Optimizing adjuvant therapy requires understanding timing, goals, and drug selection.
    • Metastatic mouse models provide insights into human cancer treatment.

    Purpose of the Study:

    • To evaluate the impact of adjuvant chemotherapy timing on efficacy in mouse models.
    • To compare relapse-free survival and cure rate as therapeutic goals.
    • To assess the predictive value of tumor response for adjuvant drug selection.

    Main Methods:

    • Administered cyclophosphamide postoperatively and preoperatively to mice with Lewis lung carcinoma (LL) or mammary carcinoma 2661 (M2661).
    • Assessed adjuvant therapy efficacy based on tumor load (small, medium, large) after surgery.

    Related Experiment Videos

  • Evaluated drug selection by comparing large tumor volume response with adjuvant therapy outcomes.

    • Main Results:

    • Postoperative adjuvant therapy was more effective in LL than M2661, with delayed treatment reducing efficacy.
    • Preoperative chemotherapy improved efficacy in M2661 but reduced it in LL.
    • Adjuvant therapy's cure rate benefit increased with decreased tumor load; lifespan increase was independent of tumor load.
    • Predicting adjuvant therapy success from large tumor response yielded false positives and negatives.

    Conclusions:

    • Adjuvant chemotherapy timing is critical and tumor-dependent.
    • Reducing residual tumor burden enhances cure rates.
    • Current methods for predicting adjuvant drug efficacy require refinement.